Preparing for a possible pandemic: influenza A/H5N1 vaccine development

Current Opinion in Pharmacology

Volumn 7, Issue 5, 2007, Pages 484-490

  Keitel, Wendy A ^a   Atmar, Robert L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; EPITOPE; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; LIVE VACCINE; MEMBRANE ANTIGEN; PLACEBO; RECOMBINANT VACCINE; SUBUNIT VACCINE; VIRUS DNA; VIRUS HEMAGGLUTININ; VIRUS VACCINE; VIRUS VECTOR;

ANTIBODY RESPONSE; CELL CULTURE; CLINICAL TRIAL; DRUG MEGADOSE; DRUG SYNTHESIS; HUMAN; HYPERPIGMENTATION; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS A H5N1; INJECTION SITE ERYTHEMA; INJECTION SITE SWELLING; PANDEMIC; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; SINGLE DRUG DOSE; VIRION; VIROGENESIS; VIRUS STRAIN;

ANIMALS; DISEASE OUTBREAKS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 35348880906     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2007.06.004     Document Type: Review

References (44)

1. Keitel W.A., and Couch R.B. Inactivated influenza virus vaccines. In: Potter C.W. (Ed). Perspectives in Medical Microbiology: Influenza (2002), Elsevier 145-177
2. Kilbourne E.D., Smith C., Brett I., Pokorny B.A., Johansson B., and Cox N. The total influenza vaccine failure of 1947 revisited: major intrasubtypic antigenic change can explain failure of vaccine in a post-World War II epidemic. Proc Natl Acad Sci USA 99 (2002) 10748-10752
3. Meiklejohn G.N. Asian influenza vaccination: dosage, routes, schedules of inoculation, and reactions. Am Rev Resp Dis 83 (1961) 175-177
4. Mostow S.R., Schoenbaum S.C., Dowdle W.R., Coleman M.T., and Kaye H.S. Studies with inactivated influenza vaccines purified by zonal centrifugation. 1. Adverse reactions and serological responses. Bull World Health Org 41 (1969) 525-530
5. Parkman P.D., Hopps H.E., Rastogi S.C., and Meyer H.M. Summary of clinical trials of influenza virus vaccines in adults. J Infect Dis 136 (1977) S722-S730
6. La Montagne J.R., Noble G.R., Quinnan G.V., Curlin G.T., Blackwelder W.C., Smith J.I., Ennis F.A., and Bozeman F.M. Summary of clinical trials of inactivated influenza vaccine-1978. Rev Infect Dis 5 (1983) 723-736
7. Peiris J.S., de Jong M.D., and Guan Y. Avian influenza virus (H5N1): a threat to human health. Clin Microbiol Rev 20 (2007) 243-267. This excellent article provides an up-to-date review of influenza A/H5N1 infections in birds and humans.
8. Shinya K., Ebina M., Yamada S., Ono M., Kasai N., and Kawaoka Y. Influenza virus receptors in the human airway. Nature 440 (2006) 435-436
9. Stephenson I., Wood J.M., Nicholson K.G., and Zambon M.C. Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin. J Med Virol 70 (2003) 391-398
10. Stephenson I., Wood J.M., Nicholson K.G., Charlett A., and Zambon M.C. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 103 (2004) 91-95
11. European Committee for Proprietary Medicinal Products: Note for guidance on harmonization of requirements for influenza vaccines. March 1997 (CPMP/BWP/214/96). European Agency for the Evaluation of Medicinal Products. March 12, 1997.
12. Food and Drug Administration. Draft guidance for industry on clinical data needed to support the licensure of trivalent inactivated influenza vaccines; availability. Fed Reg 71 (2006) 12367
13. Dennis C. Flu-vaccine makers toil to boost supply. Nature 440 (2006) 1099
14. Yuen K.Y., Chan P.K.S., Peiris M., Tsang D.N.C., Que T.L., Shortridge K.F., Cheung P.T., To W.K., Ho E.T.F., Sung R., et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 351 (1998) 467-471
15. Treanor J.J., Wilkinson B.E., Masseoud F., Hu-Primmer J., Battaglia R., O'Brien D., Wolff M., Rabinovich G., Blackwelder W., and Katz J.M. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19 (2001) 1732-1737
16. Hien T.T., Liem N.T., Dung N.T., San L.T., Mai P.P., Chau N.V.V., Suu P.T., Dong V.C., Mai L.T.Q., Thi N.T., et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 350 (2004) 1179-1188
17. Neumann G., Watanabe T., Ito H., Watanabe S., Goto H., Gao P., Hughes M., Perez D.R., Donis R., Hoffmann E., et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci USA 96 (1999) 9345-9350
18. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., and Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354 (2006) 1343-1351. Results of this clinical trial of a vaccine prepared using a licensed approach were used to support licensure of the first pre-pandemic influenza A/H5N1 vaccine by the FDA. Significantly higher dosages of antigen were necessary to stimulate responses in most of the subjects, further emphasizing the need to explore antigen-sparing approaches.
19. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., Hoschler K., and Zambon M.C. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367 (2006) 1657-1664. Addition of an aluminum-containing adjuvant elicited antibody responses that could satisfy European licensing criteria at only one of several dosage levels tested, raising questions regarding the clinical utility of this approach.
20. Minutello M., Senatore F., Cecchinelli G., Bianchi M., Andreani T., Podda A., and Crovari P. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 17 (1999) 99-104
21. Nicholson K.G., Colegate A.E., Podda A., Stephenson I., Wood J., Ypma E., and Zambon M.C. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357 (2001) 1937-1943
22. Stephenson I., Nicholson K.G., Colegate A., Podda A., Wood J., Ypma E., and Zambon M.C. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 21 (2003) 1687-1693
23. Atmar R.L., Keitel W.A., Patel S.M., Katz J.M., She D.W., El Sahly H., Pompey J., Cate T.R., and Couch R.B. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 43 (2006) 1135-1142. Addition of MF59 as an adjuvant to an inactivated avian influenza vaccine (H9N2) significantly improved serum immune responses. A single dose of adjuvanted vaccine induced a serum antibody level comparable to that achieved with two doses of non-adjuvanted vaccine.
24. Ennis F.A., Mayner R.E., Barry D.W., Manischewitz J.E., Dunlap R.C., Verbonitz M.W., Bozeman F.M., and Schild G.C. Correlation of laboratory studies with clinical responses to A/New Jersey influenza vaccines. J Infect Dis 136 (1977) S397-S406
25. Wright P.F., Thompson J., Vaughn W.K., Folland D.S., Sell S.H.W., and Karzon D.T. Trials of influenza A/New Jersey/76 virus-vaccine in normal children-overview of age-related antigenicity and reactogenicity. J Infect Dis 136 (1977) S731-S741
26. Lin J., Zhang J., Dong X., Fang H., Chen J., Su N., Gao Q., Zhang Z., Liu Y., Wang Z., et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368 (2006) 991-997. Two-10 μg doses of aluminum hydroxide-adjuvanted whole virus (WV) vaccine met European requirements for licensure of an interpandemic vaccine, suggesting that WV preparations might provide antigen sparing. However, the effect of the adjuvant is not known, because unadjuvanted vaccine was not studied.
27. Belshe R.B., Newman F.K., Cannon J., Duane C., Treanor J., Van Hoecke C., Howe B.J., and Dubin G. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 351 (2004) 2286-2294
28. Kenney R.T., Frech S.A., Muenz L.R., Villar C.P., and Glenn G.M. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 351 (2004) 2295-2301
29. Stephenson I., Gust I., Perikov Y., and Kieny M.P. Development of vaccines against influenza H5. Lancet 6 (2006) 458-460
30. Webster R.G., and Govorkova E.A. H5N1 influenza-continuing evolution and spread. N Engl J Med 355 (2006) 2174-2177
31. Smith G.J.D., Fan X.H., Wang J., Li K.S., Qin K., Zhang J.X., Vijaykrishna D., Cheung C.L., Huang K., Rayner J.M., et al. Emergence and predominance of an H5N1 influenza variant in China. Proc Natl Acad Sci USA 103 (2006) 16936-16941. This report shows that several antigenically distinct H5N1 strains are circulating in Asia, complicating the selection of a strain for use in a vaccine.
32. Stephenson I., Burgarini R., Nicholson K.G., and Zambon M.C. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 191 (2005) 1210-1216. This study reports that persons vaccinated with three doses of MF59-adjuvanted H5N3 vaccine had significantly better antibody responses to several H5N1 strains circulating in Asia compared to persons who received non-adjuvanted vaccine. The results suggest that, in addition to improving antibody responses to homologous strains, use of an adjuvant can broaden the immune response to include heterologous viruses.
33. Lipatov A.S., Webby R.J., Govorkova E.A., Krauss S., and Webster R.G. Efficacy of H5 influenza vaccines produced by reverse genetics in a lethal mouse model. J Infect Dis 191 (2005) 1216-1220
34. Lipatov A.S., Hoffman E., Salomon R., Yen H.L., and Webster R.G. Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets. J Infect Dis 194 (2006) 1040-1043
35. Govorkova E.A., Webby R., Humberd J., Seiler J.P., and Webster R.G. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis 194 (2006) 159-167
36. Hampson A. Ferrets and the challenges of H5N1 vaccine formulation. J Infect Dis 194 (2006) 143-145
37. Desheva J.A., Lu X.H., Rekstin A.R., Rudenko L.G., Swayne D.E., Cox N.J., Katz J.M., and Klimov A.I. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential. Vaccine 24 (2006) 6859-6866
38. Suguitan A.L., McAuliffe J., Mills K.L., Jin H., Duke G., Lu B., Luke C.J., Murphy B., Swayne D.E., Kemble G., et al. Live, attenuated influenza A/H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 3 (2006) 9:0001-9:0015
39. Fedson D.S. Vaccine development for an imminent pandemic. Hum Vac 2 (2006) 38-42
40. Laddy D.J., Yan J., Corbitt N., Kobasa D., Kobinger G.P., and Weiner D.B. Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine 25 (2007) 2984-2989
41. Ernst W.A., Kim H.J., Tumpey T.M., Jansen A.D.A., Tai W., Cramer D.V., Adler-Moore J.P., and Fujii G. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 24 (2006) 5158-5168
42. Luke T.C., Kilbane E.M., Jackson J.L., and Hoffman S.L. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?. Ann Intern Med 145 (2006) 599-609
43. Lu J., Guo Z., Pan X., Wang G., Zhang D., Li Y., Tan B., Ouyang L., and Yu X. Passive immunotherapy for influenza A/H5N1 virus infection with equine hyperimmune globulin F (ab′)2 in mice. Respir Res 7 (2006) 43
44. Hanson B.J., Boon A.C.M., Lim A.P.C., Webb A., Ooi E.E., and Webby R.J. Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir Res 7 (2006) 126